Loading...
Derniers dépôts
-
Valentine Poissonnet, Emilien Chabrillac, Emmanuelle Uro-Coste, Virginie Woisard, Antoine Moya-Plana, et al.. Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study. Oral Oncology, 2024, 159, pp.107072. ⟨10.1016/j.oraloncology.2024.107072⟩. ⟨hal-04824410⟩
-
Gaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, Najeeb Halabi, Eliane Mery-Lamarche, et al.. Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary study. Journal for Immunotherapy of Cancer, 2024, 12 (7), pp.e008734. ⟨10.1136/jitc-2023-008734⟩. ⟨hal-04821475⟩
-
Maud Voisin, Philippe de Médina, Arnaud Mallinger, Florence Dalenc, Emilie Huc-Claustre, et al.. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114 (44), pp.E9346-E9355. ⟨10.1073/pnas.1707965114⟩. ⟨hal-02316171⟩
-
Jean-Emmanuel Kurtz, Xavier Buy, Frédéric Deschamps, Erik Sauleau, Amine Bouhamama, et al.. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. European Journal of Cancer, 2021, 143, pp.78-87. ⟨10.1016/j.ejca.2020.10.035⟩. ⟨hal-03623642⟩
-
Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
-
Camille Franchet, Robin Schwob, Guillaume Bataillon, Charlotte Syrykh, Sarah Péricart, et al.. Bias reduction using combined stain normalization and augmentation for AI-based classification of histological images. Computers in Biology and Medicine, 2024, 171, pp.108130. ⟨10.1016/j.compbiomed.2024.108130⟩. ⟨inserm-04773423⟩
-
Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
-
Marie Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, et al.. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British Journal of Cancer, In press, ⟨10.1038/s41416-024-02804-6⟩. ⟨hal-04683939⟩
-
Mohamed Bouchahda, Valérie Boige, Denis Smith, Abdoulaye Karaboué, Michel Ducreux, et al.. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer, 2016, 68, pp.163-172. ⟨10.1016/J.EJCA.2016.09.011⟩. ⟨hal-04545408⟩
-
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
-
Coline Montégut, Jean-Sébastien Guillamo, François Ducray, Caroline Dehais, Cohen-Jonathan Moyal Elisabeth, et al.. Predictive geriatric factors in elderly patients treated for idh-mutant high-grade gliomas: a French Pola network study. Neuro-Oncology, 2021, 23 (6), pp.153. ⟨10.1093/neuonc/noab196.600⟩. ⟨hal-03600574⟩
-
Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩
-
Anne Patsouris, Kadija Diop, Olivier Tredan, Daniel Nenciu, Anthony Gonçalves, et al.. Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, pp.283-295. ⟨10.1016/j.ejca.2021.09.028⟩. ⟨hal-04522229⟩
-
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
-
Gilles Freyer, Anne Floquet, Olivier Trédan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩